Consultant360Using Hyperthermia as Antidepressant Treatment

Hyperthermia: Unlocking Anti-inflammatory Pathways for Depression Relief

Recent research led by Charles Raison, MD, at the University of Wisconsin — Madison, has shed light on the potential of mild-intensity whole-body hyperthermia as a novel treatment for major depressive disorder (MDD). By examining the association between plasma cytokines and the antidepressant response elicited by hyperthermia, this study unveils intriguing mechanisms of action and suggests broader implications for understanding and treating depression. The findings not only challenge conventional wisdom about inflammation’s role in depression but also highlight the complexity of the body’s response to stressors, offering physicians a new perspective on non-pharmacological treatments for MDD.

Key Points:

• Hyperthermia treatment involves raising the body temperature to 101.3 degrees Fahrenheit, demonstrating a rapid and sustained antidepressant effect in patients with MDD.
• Contrary to initial hypotheses, hyperthermia significantly increases levels of interleukin-6 (IL-6), a cytokine traditionally associated with inflammation and negative health outcomes, yet this spike is correlated with a decrease in depressive symptoms.
• The study posits that the temporary increase in IL-6 induced by hyperthermia initiates a compensatory anti-inflammatory response, potentially underlying its antidepressant effects.
• This research suggests that hyperthermia, like exercise, acts as a beneficial stressor that triggers the body’s adaptive mechanisms, challenging traditional views on the relationship between stress, inflammation, and depression.
• The findings underscore the importance of psychoneuroimmunology in understanding the complex interplay between the immune system and mental health, opening avenues for novel therapeutic strategies.
• Dr. Raison’s work emphasizes the need for further research to explore the long-term effects of hyperthermia on depression and its potential integration into existing treatment protocols.

“Then we said, well, man, that’s weird. IL-6 is bad. I bet that people that got undepressed, maybe they get less IL-6. It went up. We looked and we found exactly the opposite. We found that the more the IL-6 went up, the more the depression went down over the subsequent 6 weeks. This is really, really interesting. It’s really interesting if you’re into what’s called psychoneuroimmunology because it flies in the face of what we tend to think.”
– Dr. Charles Raison, Professor in the Department of Psychiatry at the University of Wisconsin – Madison

More on Depression